The review concluded that there was no evidence of a protective effect of omega-3 polyunsaturated fatty acids from fish oil against recurrent life-threatening ventricular arrhythmia in patients with an implantable cardioverter defibrillator. The authors' conclusions appeared to reflect the evidence presented, but limitations in the review methodology and the small number of included trials mean their reliability is uncertain.
Authors' objectives
To determine the effects of omega-3 polyunsaturated fatty acids from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator patients.
Searching
MEDLINE, EMBASE and the Cochrane Library were searched to May 2008; search terms were reported.
Study selection
Studies that evaluated the effects of of fish oil (omega-3 polyunsaturated fatty acids) compared with placebo for the treatment of spontaneous ventricular arrhythmia in patients with implantable cardioverter defibrillators were eligible for inclusion.
Interventions in the included trials were fish oil capsules (1.3 or 2.6g/day as ethyl esters; 0.9g/day as triglycerides) compared with placebo. Participants in the included trials had implantable cardioverter defibrillators and prior malignant ventricular tachycardia or ventricular fibrillation. Some participants were using class I and class III antiarrhythmic medication; between 70 to 80% had a history of coronary artery disease or ischaemic heart disease and had a mean ejection fraction of approximately 35%. Some participants also had a high fish intake diet at baseline. Participants mean age ranged from 61 to 66 years; the proportion of males ranged from 82 to 86%. Outcomes assessed included time to first confirmed spontaneous ventricular tachyarrhythmia, ventricular fibrillation, or death from any cause.
The authors did not state how papers were selected for inclusion.
Assessment of study quality
The authors did not formally assess validity, but stated that the included studies were randomised, double-blind, placebocontrolled trials (RCTs) with high quality standards.
Data extraction
Two trials were conducted by the authors, so individual patient data (IPD) were available; data were extracted from a third published trial. As clinical endpoints varied between trials, the authors defined common clinical endpoints and reanalysed IPD data before combining with other data. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for the time to first tachyarrhythmia or death on an intention-to-treat basis. As trial duration varied, authors extracted data up to one year.
The authors did not state how many reviewers performed the data extraction.
Methods of synthesis
For the meta-analysis hazard ratios from all included trials were combined using a random-effects model. Subgroup outcomes were corrected for baseline characteristics of patients.
